The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 -- Boehringer Ingelheim and Sitryx Therapeutics ("Sitryx"), a clinical-stage biopharmaceutical company developing novel oral therapies ...
NEW ORLEANS (AP) — A New Orleans judge ordered actor Shia LaBeouf to return to drug and alcohol rehabilitation and set a $100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results